Sigyn Therapeutics (SIGY) Free Cash Flow (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Free Cash Flow of -$199326.0 for Q3 2025, down 30.76% sequentially from -$152436.0 in Q2 2025, and down 21.68% YoY from -$254501.2 in Q3 2024.
Sigyn Therapeutics (SIGY) Free Cash Flow (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Free Cash Flow for 10 years, with the latest figure at -$199326.0 in Q3 2025.
- Quarterly Free Cash Flow fell 21.68% year-over-year to -$199326.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$936426.0 (down 31.87% YoY) and the FY2024 annual result came in at -$872436.0, up 36.93% from the prior year.
- Free Cash Flow declined to -$199326.0 in Q3 2025 per SIGY's latest filing, from -$152436.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at -$127894.0 in Q4 2023 and troughed at -$562573.0 in Q1 2023.
- A 5-year average of -$343975.9 and a median of -$328694.0 in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2021 and 2023: Free Cash Flow plunged 201.93% in 2021, then soared 71.69% in 2023.
- Over 5 years, Free Cash Flow stood at -$562020.0 in 2021, then gained by 19.62% to -$451767.0 in 2022, then jumped by 71.69% to -$127894.0 in 2023, then tumbled by 126.92% to -$290218.0 in 2024, then soared by 31.32% to -$199326.0 in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$199326.0, -$152436.0, and -$294446.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -199,326.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -199,326.00 |
| Sep 30, 2025 | -199,326.00 |
| Jun 30, 2025 | -152,436.00 |
| Jun 30, 2025 | -152,436.00 |
| Mar 31, 2025 | -294,446.00 |
| Mar 31, 2025 | -294,446.00 |
| Dec 31, 2024 | -290,218.00 |
| Dec 31, 2024 | -290,218.00 |
| Sep 30, 2024 | -163,812.00 |
| Sep 30, 2024 | -163,812.00 |
| Jun 30, 2024 | -182,794.00 |
| Jun 30, 2024 | -182,794.00 |
| Mar 31, 2024 | -235,612.00 |
| Mar 31, 2024 | -235,612.00 |
| Dec 31, 2023 | -127,894.00 |
| Dec 31, 2023 | -127,894.00 |
| Sep 30, 2023 | -364,049.00 |
| Sep 30, 2023 | -364,049.00 |
| Jun 30, 2023 | -328,694.00 |
| Jun 30, 2023 | -328,694.00 |